The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Matyushkin A.V.

Pirogov Russian National Research Medical University

Features of the course and therapeutic aspects of deep vein thrombosis in elderly and senile patients

Authors:

Matyushkin A.V.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2022;(6): 133‑139

Read: 3114 times


To cite this article:

Matyushkin AV. Features of the course and therapeutic aspects of deep vein thrombosis in elderly and senile patients. Pirogov Russian Journal of Surgery. 2022;(6):133‑139. (In Russ.)
https://doi.org/10.17116/hirurgia2022061133

Recommended articles:
Hemo­rrhagic and thro­mboembolic complications in catheter abla­tion for atrial fibrillation. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(6):628-633
Ranking of mechanical thro­mboprophylaxis methods in surgery: a network meta-analysis. Medi­cal Technologies. Asse­ssment and Choice. 2026;(1):143-152

References:

  1. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41:3-14. 
  2. Lankeit M, Konstantinides S. Mortality Risk Assessment and the Role of Thrombolysis in Pulmonary Embolism. Clin Chest Med. 2010;31:759-769. 
  3. Spencer FA, Gore JM, Lessard D, Emery C, Pacifico L, Reed G, Gurwitz JH, Goldberg RJ. Venous Thromboembolism in the Elderly: A Community-Based Perspective. Thromb Haemost. 2008;100:780. 
  4. Méan M, Righini M, Jaeger K, Beer HJ, Frauchiger B, Osterwalder J, Kucher N, Lämmle B, Cornuz J, Angelillo-Scherrer A, Rodondi N, Limacher A, Trelle S, Matter CM, Husmann M, Banyai M, Aschwanden M, Egloff M, Mazzolai L, Hugli O, Bounameaux H, Aujesky D. The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. J Thromb Thrombolysis. 2013;36:475-483. 
  5. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G; Italian Federation of Anticoagulation Clinics. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124:824-829. 
  6. Nieto JA, De Tuesta AD, Marchena PJ, Tiberio G, Todoli JA, Samperiz AL, Monreal M; Riete Investigators. Clinical outcome of patients with venous thromboembolism and recent major bleeding: Findings from a prospective registry (RIETE). J Thromb Haemost. 2005;3:703-709. 
  7. Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, Ten Cate-Hoek AJ, Elalamy I, Enzmann FK, Geroulakos G, Gottsäter A, Hunt BJ, Mansilha A, Nicolaides AN, Sandset PM, Stansby G, Esvs Guidelines Committee, de Borst GJ, Bastos Gonçalves F, Chakfé N, Hinchliffe R, Kolh P, Koncar I, Lindholt JS, Tulamo R, Twine CP, Vermassen F, Wanhainen A, Document Reviewers, De Maeseneer MG, Comerota AJ, Gloviczki P, Kruip MJHA, Monreal M, Prandoni P, Vega de Ceniga M. Editor’s Choice — European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021;61:9-82. 
  8. Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular Trends in Occurrence of Acute Venous Thromboembolism: The Worcester VTE Study (1985—2009). Am J Med. 2014;127:829-839. 
  9. Bell EJ, Lutsey PL, Basu S, Cushman M, Heckbert SR, Lloyd-Jones DM, Folsom AR. Lifetime Risk of Venous Thromboembolism in Two Cohort Studies. Am J Med. 2016;129:339.e19-339.e26. 
  10. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Trends in the Incidence of Deep Vein Thrombosis and Pulmonary Embolism. Arch Intern Med. 1998;158:585. 
  11. Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, Gore JM, Goldberg RJ. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis. 2009;28:401-409. 
  12. Kim TM, Kim JS, Han SW, Hong YS, Kim I, Ha J, Kim SJ, Chung JW, Park JH, Lee D, Park S, Kim BK, Kim NK, Yoon SS. Clinical predictors of recurrent venous thromboembolism: A single institute experience in Korea. Thromb Res. 2009;123:436-443. 
  13. Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, Heinze G, Kyrle PA. Overweight, Obesity, and the Risk of Recurrent Venous Thromboembolism. Arch Intern Med. 2008;168:1678.
  14. Silverstein RL, Bauer KA, Cushman M, Esmon CT, Ershler WB, Tracy RP. Venous thrombosis in the elderly: more questions than answers. Blood. 2007;110:3097-3101.
  15. Folsom AR, Boland LL, Cushman M, H. et al. Frailty and risk of venous thromboembolism in older adults. J Gerontol A Biol Sci Med Sci. 2007;62:79-82. 
  16. Ageno W, Agnelli G, Imberti D, Moia M, Palareti G, Pistelli R, Rossi R, Verso M. Risk factors for venous thromboembolism in the elderly: results of the master registry. Blood Coagul Fibrinolysis. 2008;19:663-667. 
  17. Di Minno G, Mannucci PM, Tufano A, Palareti G, Moia M, Baccaglini U, Rudelli G, Giudici GA. The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. J Thromb Haemost. 2005;3:1459-1466.
  18. Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost. 2010;8:2105-2112.
  19. White R, Zhou H, Romano P. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90:446-455. 
  20. Noboa S, Mottier D, Oger E. Estimation of a potentially preventable fraction of venous thromboembolism: a community-based prospective study. J Thromb Haemost. 2006;4:2720-2722.
  21. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Case-Control Study. Arch Intern Med. 2000;160:809. 
  22. Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529-535. 
  23. Delluc A, Ianotto JC, Tromeur C, De Moreuil C, Couturaud F, Lacut K, Le Moigne E, Louis P, Thereaux J, Metges JP, Mottier D. Real-world incidence of cancer following a first unprovoked venous thrombosis: Results from the EPIGETBO study. Thromb Res. 2018;164:79-84. 
  24. Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum Lipid Levels and the Risk of Venous Thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:1970-1975.
  25. Roach REJ, Lijfering WM, Flinterman LE, Rosendaal FR, Cannegieter SC. Increased risk of CVD after VT is determined by common etiologic factors. Blood. 2013;121:4948-4954.
  26. Chen Y, Zhou HX, Hu YH, et al. Risk factors of pulmonary embolism in senile and non-senile inpatients and the predictive value of Caprini risk assessment model in these two populations. Zhonghua Yi Xue Za Zhi. 2017;97:755-760. 
  27. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment. Chest. 2008;133:257-298. 
  28. van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124:1968-1975.
  29. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, Hirsh J, Kearon C. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342:d3036-d3036.
  30. Chechulova AV, Tomchenko AI, Nokhrin SP, Soroka VV, Khomchuk IA. Bleeding in elderly and senile patients with deep vein thrombosis on anticoagulant therapy. Flebologiya. 2021;15(3):170-176. (In Russ.).
  31. Khan F, Rahman A, Carrier M, Kearon C, Weitz JI, Schulman S, Couturaud F, Eichinger S, Kyrle PA, Becattini C, Agnelli G, Brighton TA, Lensing AWA, Prins MH, Sabri E, Hutton B, Pinede L, Cushman M, Palareti G, Wells GA, Prandoni P, Büller HR, Rodger MA. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366:l4363. https://doi.org/10.1136/bmj.l4363
  32. Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, Crowther M. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2018;16:1288-1295.
  33. Khruslov MV. Extended Antithrombotic Therapy in Elderly Patients with Deep Venous Thrombosis. Flebologiya. 2015;9(3):41-46. (In Russ.).
  34. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-352. 
  35. Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018;154:1121-1201.
  36. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, Carrier M. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA. 2014;312:1122-1135.
  37. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124:2450-2458.
  38. Van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124:1968-1975.
  39. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI. Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2013;368:699-708. 
  40. Weitz JI, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Holberg G, Kakkar A, Lensing AW, Prins M, Haskell L, van Bellen B, Verhamme P, Wells PS, Prandoni P. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Thromb Haemost. 2015;114:645-650. 

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.